Instead, the identification of Her4 either by immunohistochemistry [10-13], fluorescence in-situ hybridization (FISH) [14,16], or qPCR [22] seems to be sufficient for attributing a positive impact on the course/outcome of breast cancer disease. This evidence concerns the gene ERBB4 and breast cancer.